Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Published:2023-07 Issue:10399 Volume:402 Page:373-385
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Platzbecker Uwe,Della Porta Matteo Giovanni,Santini Valeria,Zeidan Amer M,Komrokji Rami S,Shortt Jake,Valcarcel David,Jonasova Anna,Dimicoli-Salazar Sophie,Tiong Ing Soo,Lin Chien-Chin,Li Jiahui,Zhang Jennie,Giuseppi Ana Carolina,Kreitz Sandra,Pozharskaya Veronika,Keeperman Karen L,Rose Shelonitda,Shetty Jeevan K,Hayati Sheida,Vodala Sadanand,Prebet Thomas,Degulys Andrius,Paolini Stefania,Cluzeau Thomas,Fenaux Pierre,Garcia-Manero Guillermo

Funder

Bristol-Myers Squibb Co Summit

Acceleron Pharma

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

General Medicine

Reference20 articles.

1. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms;Khoury;Leukemia,2022

2. How we treat lower-risk myelodysplastic syndromes;Fenaux;Blood,2013

3. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016